OncoTricks

Low counts, rectal cancer and bortezomib, Nov 10, 2026

Two lines low, reticulocytes low

On the floor

30s, admitted for something else. Hemoglobin 6.5, MCV 64, platelets 85K, white count normal, reticulocytes low.

Reticulocyte: red cell 1 day out of the marrow. Low reticulocytes: the marrow is not making, so this is not bleeding or destruction. ATRA: all-trans retinoic acid. PNH: paroxysmal nocturnal hemoglobinuria.

Algorithm

yesnoTwo lines low, reticulocytes lowthe marrow is not makingDanger now?blasts, fever with neutropenia,platelets under 10,000, abnormal clottingSame dayantibiotics in 1 hour if febrileplatelets if under 10,000Promyelocytic leukemia possible:ATRA now, platelets over 30-50K,fibrinogen over 150flow cytometry, call hematologySmear and fuel labsferritin, B12, folate, copperHemolysis labs positive?B12 or folate, PNH flow,Coombs (Evans), parvovirusFuel lowiron, B12, folate or copperSmear abnormalblasts, dysplasia, teardrops,nucleated red cellsFuel normal,smear blandReplete todayiron explains the anemia,not the low plateletsFlow cytometryand marrow nowReversible causesdrugs, alcohol, big spleen, pregnancyHIV, hepatitis, EBV, CMV, parvovirusTwo lines low:marrow before dischargeStill low?Bone marrow aspirate and biopsycytogenetics and myeloid gene panelEmpty: aplastic anemiaPNH flow cytometry, HLA typing,inherited testing if under 40,irradiated, leukoreduced bloodFull and dysplastic:myelodysplasiagene panel, risk scoreInvadedleukemia, lymphoma,cancer, fibrosis

Order tonight

  • CBC with differential, smear to the lab
  • Absolute reticulocyte count
  • Immature platelet fraction
  • Ferritin, iron, TIBC
  • B12 with methylmalonic acid, folate
  • Copper, zinc
  • LDH, haptoglobin, bilirubin, direct Coombs
  • PT, INR, fibrinogen
  • Peripheral flow cytometry: PNH and blasts
  • HIV, hepatitis B and C, parvovirus B19
  • Pregnancy test

Write it like this

Bicytopenia with low reticulocyte count, consistent with decreased production. Severe iron deficiency explains the anemia but not the thrombocytopenia. Primary marrow process, including acute leukemia, must be excluded before discharge. Plan: IV iron, peripheral flow cytometry, hemolysis labs, bone marrow aspirate and biopsy with cytogenetics this admission. Source of iron loss: menstrual and GI history, celiac serology, GI evaluation.

Where people slip

  • Iron deficiency explains the anemia. Do not let it explain away low platelets: a leukemia sent home is the miss you never get back.
  • Folate before B12 fixes the blood and lets the nerves get worse.
  • Blood from relatives if aplastic anemia is possible: they are future donors.

3 F: Fuel (iron, B12, folate, copper). Factory (aplastic anemia, myelodysplasia, PNH). Foreign cells (leukemia, lymphoma, cancer).

Sources

Retrieved from PubMed, read on Nov 9, 2026.

  1. Durrani J, Groarke EM, Sekeres MA. Bone marrow failure syndromes across the age spectrum. EClinicalMedicine 2026. doi:10.1016/j.eclinm.2026.104139
  2. Killick SB, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016. doi:10.1111/bjh.13853
  3. van den Akker M, et al. Thrombocytopenia in severe iron deficiency anemia in children. Health Sci Rep 2021 (pediatric series). doi:10.1002/hsr2.351
  4. Sanz MA, et al. Management of acute promyelocytic leukemia: updated European LeukemiaNet recommendations. Blood 2019. doi:10.1182/blood-2019-01-894980

Pancytopenia in the ICU

Consult from the ICU

60s, septic shock last week, now off pressors. White count 2, hemoglobin 8, platelets 40, then 21, then 12.

Better patient, worse counts: it is not the sepsis anymore. 4T score (0 to 8) estimates heparin-induced thrombocytopenia. HScore estimates HLH, hemophagocytic lymphohistiocytosis, the immune storm that eats blood cells. DIC: disseminated intravascular coagulation. TTP: thrombotic thrombocytopenic purpura. HIT: heparin-induced thrombocytopenia. PLASMIC: 7-point TTP score.

Algorithm

noyesnone of thesePancytopenia in the ICUsepsis improving, counts still fallingReal?clumps on the smear, dilutionRepeat in citrate tuberecheck after fluidsSmear, LDH, haptoglobin, D-dimer,fibrinogen, INR, heparin, ferritinConsumptionhigh INR, D-dimer up,falling fibrinogenSchistocytesnormal INRHeparin and4T score 4 or moreFever, ferritinin the thousands,big liver or spleenDICISTH score,treat the cause,replace if bleedingPossible TTPADAMTS13 BEFORE exchangePLASMIC 6 to 7:plasma exchange nowHITstop all heparin,send PF4 antibody,argatroban or bivalirudinHScore 168 or more:call hematology,soluble CD25, triggerunder 168: recheck dailyNone of these:not making, or pooling in the spleenDrugslinezolid, vancomycin,piperacillin-tazo,ganciclovir, trimeth-sulfa,methotrexateCopper, folate, B12tube feeds, dialysis,gastric surgeryVirusesCMV, EBV, parvovirus,HIVSpleencirrhosis, portalhypertensionBone marrow biopsyif still falling, nucleated red cellson the smear, or a cancer history

Order today

  • Smear review: clumps, schistocytes, nucleated red cells
  • LDH, haptoglobin, fibrinogen, INR, D-dimer
  • Reticulocytes, creatinine (PLASMIC score)
  • PF4 antibody if 4T is 4 or more
  • Ferritin, triglycerides, soluble CD25 if HLH possible
  • Copper, zinc, B12, folate
  • CMV, EBV, parvovirus B19 PCR
  • Medication list with pharmacy

Write it like this

Progressive pancytopenia despite improving sepsis. Differential: drug-induced marrow suppression, copper deficiency, secondary HLH, marrow infiltration. No evidence of DIC or TMA; HIT unlikely by 4T score. Plan: viral PCRs, copper, triglycerides for HScore, medication review; bone marrow biopsy if counts keep falling.

Where people slip

  • Ferritin 2,000 in sepsis is not enough for HLH. In the ICU, HLH sits around 9,000 and up, and even a high HScore is right only about 1 time in 5.
  • Linezolid after 2 weeks, ganciclovir, trimethoprim-sulfamethoxazole, methotrexate with kidney failure: check the list before the marrow.
  • Copper deficiency looks like myelodysplasia on the marrow. Check it before calling it a clonal disease.
Sources

Retrieved from PubMed, read on Nov 9, 2026.

  1. Knaak C, et al. HLH in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care 2020. doi:10.1186/s13054-020-02941-3
  2. Lachmann G, et al. Hyperferritinemia in critically ill patients. Crit Care Med 2020. doi:10.1097/CCM.0000000000004131
  3. Fardet L, et al. Development and validation of the HScore. Arthritis Rheumatol 2014. doi:10.1002/art.38690
  4. Halfdanarson TR, et al. Hematological manifestations of copper deficiency. Eur J Haematol 2008. doi:10.1111/j.1600-0609.2008.01050.x
  5. Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020. doi:10.1111/jth.15006

Rectal cancer

New consult

28-year-old, rectal mass, biopsy adenocarcinoma, MRI T3N1, nothing in the chest or liver. What do you ask first?

dMMR: mismatch repair deficient; usually also MSI-high (microsatellite instability). FOLFOX, CAPOX: oxaliplatin with 5-FU or capecitabine. T: depth (T3 through the wall, T4 into organs). N: nodes (N1 1 to 3, N2 4 or more).

Algorithm

deficientproficientRectal adenocarcinoma, no metastasesrectal MRI, CT chest, abdomen, pelvis, CEAMismatch repair staining:deficient?Stage II to III: dostarlimab500 mg every 3 weeks, 9 dosesStage I: tumor board,surgery is standardProficient:where does the MRI put it?Restage at weeks 6 and 12and after dose 9MRI, endoscopy, CTEarlyT1 to T2,node negativeIntermediateT2N1, T3N0 to N1,mid or upper rectumHigh risklow, T4, N2,fascia 1 mm or less,vein invasion,side-wall nodesComplete: watch and waitTumor left: tumor board(chemoradiation or surgery)Surgerytotal mesorectalexcisionFOLFOX, 6 cyclesPROSPECT trialChemoradiation,then FOLFOX or CAPOXOPRA trialShrank 20% or more:surgery, then6 more FOLFOXLess: chemoradiation,then surgeryMRI and endoscopyComplete or nearcomplete: watch and waitTumor left: surgeryWatch and wait: endoscopy every 3 to 4 months and MRI every 6 months for 2 years

The two dostarlimab studies

Memorial Sloan KetteringAZUR-1
DesignOne center, phase 2Many centers, phase 2
Patients12 in 2022; 49 rectal by 2025154
Complete response at end of treatment49 of 49not reported
Overall response100%79%central review; 82% investigators
Complete response still there at 12 months93%FDA review, 50 patients47 to 68%central review 47%, investigators 68%
Dose500 mg IV every 3 weeks, 9 doses (6 months). FDA approved Oct 19, 2026, for stage II to III.

Why the gap: AZUR-1 used an independent central review as well as investigators, across many centers instead of one. Tell the patient: most respond, about half to two thirds still have no tumor at 1 year, and surgery stays available.

Order before tumor board

  • Rectal protocol MRI
  • CT chest, abdomen, pelvis; CEA
  • Mismatch repair staining on the biopsy
  • Genetics referral (under 50: germline panel for everyone)
  • Fertility referral before any treatment
  • Before PD-1 blockade: TSH, cortisol, liver tests, hepatitis B and C; pregnancy test

Write it like this

Rectal adenocarcinoma, clinical T3N1M0, mismatch repair deficient. Recommend PD-1 blockade with dostarlimab with intent of organ preservation, restaging with MRI, endoscopy and CT at weeks 6 and 12 and after dose 9. Germline testing for Lynch syndrome and fertility preservation before therapy. Tumor board.

Where people slip

  • Chemoradiation booked before the staining is back. In a dMMR tumor it may be radiation the patient never needed.
  • Promising 100%. That was one center. Quote AZUR-1.
  • Watch and wait without watching: 94% of regrowths come in the first 2 years.

Stain before you plan. Young patient, three calls: genetics, fertility, tumor board.

Sources

Retrieved from PubMed and FDA news reports, read on Nov 9, 2026.

  1. Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022. doi:10.1056/NEJMoa2201445
  2. Cercek A, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025. doi:10.1056/NEJMoa2404512
  3. FDA accelerated approval of dostarlimab for dMMR or MSI-high locally advanced rectal cancer, AZUR-1 (NCT05723562). OncLive, Oct 19, 2026. onclive.com
  4. Verheij FS, et al. Long-term results of organ preservation with total neoadjuvant therapy: the OPRA trial. J Clin Oncol 2024. doi:10.1200/JCO.23.01208
  5. Schrag D, et al. Preoperative treatment of locally advanced rectal cancer (PROSPECT). N Engl J Med 2023. doi:10.1056/NEJMoa2303269
  6. Scott AJ, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol 2024. doi:10.1200/JCO.24.01160
  7. Pearlman R, et al. Germline mutations among patients with early-onset colorectal cancer. JAMA Oncol 2017. doi:10.1001/jamaoncol.2016.5194

Bortezomib: once or twice a week?

From rounds

78-year-old, new myeloma, kidneys failed from light chains, on dialysis, diabetic neuropathy in both feet. The fellow asks: should we go twice a week?

Cast nephropathy: free light chains clog the kidney tubules; the faster they fall, the better the kidney's chance. Free light chains: the blood test that tracks it. Weekly: days 1, 8, 15, 22 every 28 days. Twice weekly: days 1, 4, 8, 11 every 21 days, at least 72 hours apart.

Algorithm

yesnoyesnoyesnoBortezomib in myeloma: which schedule?subcutaneous, 1.3 mg/m2 per doseEmergency?kidneys failing from light chains, plasma cell leukemia,extramedullary disease, severe hypercalcemia, cord compressionTwice weekly: days 1, 4, 8, 11with baseline neuropathy or infection:weekly first, intensify if chains stallNeuropathy, diabetes, over 75, frail,or long-term treatment?Free light chains on days 8 and 15:falling steeply?Yes: weeklydays 1, 8, 15, 22No: weekly preferredtwice weekly only tocopy a trial protocolYes: go to weeklyonce kidneys recoverNo: intensifyadd daratumumab,call the myeloma teamNeuropathy: grade 1 with pain or grade 2, drop to 1.0 mg/m2. Grade 2 with pain or grade 3, hold,then restart at 0.7 mg/m2 once weekly. Grade 4, stop for good.

What the studies show

StudyWhoDisease controlNeuropathy
Bringhen, Blood 2010511 older patients, phase 3 trial switched from twice weekly to weekly mid-study3-year PFS 50% weekly vs 47% twice8% vs 28%grade 3 or 4
Moreau, Lancet Oncol 2011222 relapsed, randomized subcutaneous vs IV, both twice weeklyResponse 42% vs 42%6% vs 16%grade 3 or worse
Cook, Am J Hematol 2021555 new patients on VRd, Mayo ClinicTwice weekly reached best response faster; same PFS and survivalMore with twice weekly
Hoff, Blood Cancer J 20242,497 new patients, US real-world dataPFS 37.2 vs 39.6 months, no difference18.5% vs 34.7%weekly vs twice

Bottom line: twice weekly gets the response faster, not longer. It buys speed and costs nerves. PFS here is progression-free survival.

Why the kidney changes the answer

StudyWhat it showed
Hutchison, Clin J Am Soc Nephrol 200919 patients on dialysis from cast nephropathy. The 13 with a sustained early fall in free light chains (median 85%) all came off dialysis, at a median of 27 days. Of 6 whose chemotherapy was interrupted by infection, only 1 recovered.
MYRE, Bridoux, JAMA 201798 patients with biopsy-proven cast nephropathy, all on bortezomib and dexamethasone, randomized to two dialysis filters. Off dialysis at 3 months: 41% vs 33% (not significant); at 12 months: 61% vs 38%. It tested the filter, not the bortezomib schedule or cyclophosphamide.

Read together: in cast nephropathy the clock is the light chain level. Interrupted chemotherapy is the real enemy, which is why an infection on board weighs heavily.

Order and check

  • Serum free light chains on days 1, 8 and 15
  • Neuropathy grade before every dose
  • Platelets before every dose
  • Acyclovir for zoster prophylaxis
  • On dialysis: give after the session; no renal dose change
  • Liver: bilirubin over 1.5 times normal, start at 0.7 mg/m2

Write it like this

Newly diagnosed multiple myeloma with dialysis-dependent acute kidney injury, presumed light chain cast nephropathy, renal biopsy pending. Bortezomib-based induction with subcutaneous bortezomib weekly given baseline diabetic neuropathy and active infection. Serum free light chains on days 8 and 15; if not falling steeply, will intensify bortezomib to twice weekly or add daratumumab. Neuropathy assessed before each dose.

Where people slip

  • Twice weekly for everyone. It doubles neuropathy without longer disease control outside an emergency.
  • Waiting for the end of cycle 1 to look at light chains in cast nephropathy. Day 8 and 15 tell you whether the kidney has a chance.
  • IV instead of subcutaneous. Same response, a third of the severe neuropathy.

Twice weekly buys speed, not survival. The kidney is the emergency; the nerve is the price.

Sources

Retrieved from PubMed and the FDA label, read on Nov 9, 2026.

  1. Bringhen S, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010. doi:10.1182/blood-2010-07-294983
  2. Moreau P, et al. Subcutaneous versus intravenous bortezomib in relapsed multiple myeloma. Lancet Oncol 2011. doi:10.1016/S1470-2045(11)70081-X
  3. Cook J, et al. Outcomes with different administration schedules of bortezomib in VRd as first-line therapy. Am J Hematol 2021. doi:10.1002/ajh.26074
  4. Hoff FW, et al. Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. Blood Cancer J 2024. doi:10.1038/s41408-024-01034-6
  5. Hutchison CA, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009. doi:10.2215/CJN.04590908
  6. Bridoux F, et al. High-cutoff vs conventional hemodialysis in myeloma cast nephropathy (MYRE). JAMA 2017. doi:10.1001/jama.2017.17924
  7. Bortezomib (Velcade) prescribing information, FDA: dosing, neuropathy and liver dose changes.